Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

CROI 2011: Low Vitamin D Levels Less Likely with Rilpivirine than Efavirenz

HIV positive people who use antiretroviral regimens containing the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (TMC278) saw smaller changes in their vitamin D levels and were less likely to develop severe deficiency than people taking efavirenz, according to a presentation at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) this month in Boston. alt

Read more:

Once-daily Raltegravir Found Less Effective than Twice-Daily Dosing

In treatment-naive HIV patients the integrase inhibitor raltegravir (Isentress) taken once-daily was inferior to twice-daily dosing, according to findings from the QDMRK study presented this week at the 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) in Boston. The difference in efficacy was especially pronounced among people with low baseline viral load.


Read more:

Twice-daily Raltegravir Works Better than Once-daily for First-line HIV Treatment

Merck announced this week that it has halted a Phase 3 study of once-daily administration of its integrase inhibitor raltegravir (Isentress), after 48-week data showed that twice-daily dosing did a better job of maintaining HIV suppression in treatment-naive patients. The non-inferiority of twice-daily dosing was particularly evident in people who were starting antiretroviral therapy (ART) for the first time with a high viral load.

Read more:

ViiV Joins Welvista Program for People on ADAP Waiting Lists

ViiV Healthcare -- the HIV specialty company formed by GlaxoSmithKline and Pfizer -- announced this week that it will now participate in the Welvista program, a collaborative initiative to provide antiretroviral medications to low-income people on AIDS Drug Assistance Program (ADAP) waiting lists, which are growing in several states in the wake of the ongoing financial crisis.

Read more:

Merck Expands Co-pay Assistance Program for Raltegravir (Isentress)

Merck announced last week that it has expanded its co-pay assistance program for the integrase inhibitor raltegravir (Isentress). The program will now offer assistance for eligible patients with private insurance who have out-of-pocket copays.

Read more: